title: In vitro surfactant structure-toxicity relationships: implications for surfactant use in sexually transmitted infection prophylaxis and contraception.
abstract: BACKGROUND
  The need for woman-controlled, cheap, safe, effective, easy-to-use and easy-to-store topical applications for prophylaxis against sexually transmitted infections (STIs) makes surfactant-containing formulations an interesting option that requires a more fundamental knowledge concerning surfactant toxicology and structure-activity relationships.
  
  
  RESULTS
  We report in vitro effects of surfactant concentration, exposure time and structure on the viability of mammalian cell types typically encountered in the vagina, namely, fully polarized and confluent epithelial cells, confluent but non-polarized epithelial-like cells, dendritic cells, and human sperm. Representatives of the different families of commercially available surfactants--nonionic (Triton X-100 and monolaurin), zwitterionic (DDPS), anionic (SDS), and cationic (C(n)TAB (n = 10 to 16), C(12)PB, and C(12)BZK)--were examined. Triton X-100, monolaurin, DDPS and SDS were toxic to all cell types at concentrations around their critical micelle concentration (CMC) suggesting a non-selective mode of action involving cell membrane destabilization and/or destruction. All cationic surfactants were toxic at concentrations far below their CMC and showed significant differences in their toxicity toward polarized as compared with non-polarized cells. Their toxicity was also dependent on the chemical nature of the polar head group. Our results suggest an intracellular locus of action for cationic surfactants and show that their structure-activity relationships could be profitably exploited for STI prophylaxis in vaginal gel formulations. The therapeutic indices comparing polarized epithelial cell toxicity to sperm toxicity for all surfactants examined, except C(12)PB and C(12)BZK, does not justify their use as contraceptive agents. C(12)PB and C(12)BZK are shown to have a narrow therapeutic index recommending caution in their use in contraceptive formulations.
  
  
  CONCLUSIONS
  Our results contribute to understanding the mechanisms involved in surfactant toxicity, have a predictive value with regard to their safety, and may be used to design more effective and less harmful surfactants for use in topical applications for STI prophylaxis.
authors: Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
authors: Ângela S
authors: ÂS
authors: Inácio
authors: Katia A
authors: KA
authors: Mesquita
authors: Marta
authors: M
authors: Baptista
authors: João
authors: J
authors: Ramalho-Santos
authors: Winchil L C
authors: WL
authors: Vaz
authors: Otília V
authors: OV
authors: Vieira
references: J Infect Dis. 2001 Aug 15;184(4):418-28
references: 11471099
references: Lipids. 1990 Feb;25(2):119-21
references: 2329923
references: Health Care Women Int. 2002 Feb;23(2):163-72
references: 11868963
references: J Thromb Thrombolysis. 1999 Apr;7(2):137-43
references: 10364779
references: Antimicrob Agents Chemother. 2005 Apr;49(4):1509-20
references: 15793133
references: PLoS One. 2008 Jan 23;3(1):e1474
references: 18213382
references: JAMA. 2000 Aug 23-30;284(8):949
references: 10944622
references: Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9835-40
references: 18606986
references: Antimicrob Agents Chemother. 1998 Dec;42(12):3123-9
references: 9835502
references: J Phys Chem B. 2005 May 26;109(20):10458-63
references: 16852267
references: Exp Cell Res. 1992 Nov;203(1):115-27
references: 1426034
references: PLoS One. 2008 Aug 06;3(8):e2913
references: 18682796
references: Sex Transm Dis. 2006 Oct;33(10 Suppl):S153-66
references: 17003680
references: Immunity. 2007 Feb;26(2):257-70
references: 17306567
references: J Virol. 1998 Oct;72(10):7822-9
references: 9733818
references: Biophys J. 2004 Jul;87(1):353-65
references: 15240470
references: Biophys J. 2007 Dec 15;93(12):4244-53
references: 17766353
references: N Engl J Med. 1998 Aug 20;339(8):504-10
references: 9709043
references: Biophys J. 2005 Jun;88(6):4064-71
references: 15792982
references: Ann N Y Acad Sci. 2007 Jan;1095:1-6
references: 17404011
references: Annu Rev Biophys Biomol Struct. 2004;33:269-95
references: 15139814
references: Curr HIV/AIDS Rep. 2009 Feb;6(1):20-8
references: 19149993
references: Biophys J. 2006 Aug 1;91(3):873-81
references: 16617082
references: Antimicrob Agents Chemother. 2000 Jul;44(7):1954-60
references: 10858360
references: Annu Rev Biophys Biophys Chem. 1986;15:163-93
references: 2424473
references: Retrovirology. 2010 Nov 29;7:98
references: 21114823
references: Eur J Immunol. 1995 Aug;25(8):2163-9
references: 7664779
references: Toxicol Lett. 2008 Feb 28;177(1):74-82
references: 18281165
references: Antimicrob Agents Chemother. 2002 Mar;46(3):605-14
references: 11850238
references: J Leukoc Biol. 2009 Feb;85(2):205-14
references: 18818373
references: J Drugs Dermatol. 2007 Oct;6(10):991-8
references: 17966176
references: Anal Biochem. 1986 Feb 1;152(2):250-5
references: 3963361
references: Contraception. 2000 Sep;62(3):149-54
references: 11124363
references: Antiviral Res. 1999 Oct;43(3):157-73
references: 10551374
references: Nat Immunol. 2001 Apr;2(4):361-7
references: 11276208
references: Adv Ther. 2002 Sep-Oct;19(5):219-28
references: 12539882
references: Toxicol In Vitro. 1999 Aug-Oct;13(4-5):719-22
references: 20654540
references: BMC Infect Dis. 2006 Jun 01;6:90
references: 16740164
references: J Infect Dis. 2009 Aug 15;200(4):599-608
references: 19586414
references: J Pharm Sci. 2005 Apr;94(4):730-44
references: 15682384
references: Langmuir. 2006 Apr 11;22(8):3735-43
references: 16584250
references: J Antimicrob Chemother. 2006 Oct;58(4):760-7
references: 16885181
references: PLoS One. 2009 Oct 19;4(10):e7499
references: 19838303
references: Pharmazie. 1996 Mar;51(3):135-44
references: 8900863
references: JAMA. 1992 Jul 22-29;268(4):477-82
references: 1320133
references: Langmuir. 2008 Oct 21;24(20):11743-51
references: 18795806
references: Amino Acids. 2001;21(2):185-94
references: 11665814
references: J Pharm Sci. 1999 Jan;88(1):28-33
references: 9874698
references: PLoS One. 2007 Dec 19;2(12):e1312
references: 18091987
references: Lancet. 2006 Aug 5;368(9534):431-3
references: 16890813
references: Drugs. 2010 Jul 9;70(10):1231-43
references: 20568831
references: Biochem Pharmacol. 1990 Sep 15;40(6):1323-8
references: 2403386